We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Investor1978
Apr '22
annual net cash outflow a mere £34k for this last year
share4
Apr '22
356k decrease in cash in 1 year
Laura2022
9 Jun '22
The Costs of the operating business (net cash used I operating activities) is c £40k
Trading update
Thu, 7th Jul 2022
During the year the Company made planned investments in the hiring of three new staff members (two technical and the new Head of Business Development) which contributed to net cash outflows of £356k.
Thanks smkr
Is this a new PYC recruitment?
Decent recruiting
https://www.researchgate.net/profile/Cristian-Gradinaru-3
Cristian Gradinaru
AstraZeneca | AZ · Global Medicines Development
iloveshushi, You're making incorrect and possibly foolish sweeping statements. On the 24th of July 2020 I sold at 16.36p. All had been bought at single figures. I've since bought back, largely this year and the last, again in single figures. I am well in profit. As for 85% losing money in shares (never mind 99.99%!) This is plainly wrong as the vast majority of the UK working population are enrolled in pension schemes which have a large proportion of their funds in shares. My own personal Pension und has done very well thank you over the years as has my Company Pension scheme.
I wonder if you have any pension schemes - if so have a look. In addition have a look at the stellar performance of some of the Investment Trust market. Millions of UK holders have had great successes there. Lastly look at the Stocks and Shares ISA market. Again some real tax free money being made.
Good results and some good talented people recruited , what's not to like. May even get my original investment money back at some time in the future , I live in hope.
The truth hurts sometimes?
Is there any companies you DO like Nomlungu
All you seem to do is criticise and post negative posts on multiple discussion boards ?
Which companies DO you rate as a good investment?
Record Revs.
Approaching break even.
Cash runway for 2yrs +
Growing business.
Revenue to market cap only 1:3
What is the point of the company even being listed? Remove regulatory costs and profits would probably double.
Today's update confirms the numbers from March which were record revenues for H1 and H2 which combined amount to £850k and growth signalled by increased spending on new recruitment
And VAL 201 nearing it's belated conclusion (see VAL RNS) plus a growing blue chip client list
Unlike alot of small caps in 2022 PYC has very clear and significant cash run way
Unlike alot of bio techs who've had to come to the market last 3mths
Sushi, so your original comment of no one will make money is incorrect, people have made money.
Next.
1st post from someone who looks like they spend all their time on the THG discussion boards , clearly knows nothing about the comapny
Very odd
kid
Easy to look at a graph and see when and where money could be made and that is hind-sight. 85% of people loose money in shares. Just a fact. I would say that percentages probably goes to 99.99 of people who bought in. So I am sure people will not make money here they have not. (apart from the odd exception.
This is a charity. With more staff cash remaining will soon be exhausted and they will not make cash with extensions. This is a charity and soon or later when they are back for more cash as it is the only place it gets its cash, Shareholders, when Shareholder cotton on that this is going nowhere and refuse, its admin.
Its almost down to the place where it was when it jumped to 16. Now it would not surprise me how many bought at £20.00 (compounded) down 98.72%. No one will make money here as no one has.
Strong Sell.
Last raise was 2020
"No one will make money from this"
Wrong, money was made when it was sub 1p and sold on way up to 16p
no one will make money from this. What it receives on income for some odd computer analysis does not pay the salaries. So where will the money come from for that? The company says it has strong cash position? Its guaranteed it will come back to the market again for an other hand-out. This really is just a charity. Sooner or later investors will refuse taking more and more shares and when that happens its admin. This company is like a blood sucker. Its going to make little money from those contracts or extensions of contracts and follow ons.
STRONG SELL.
Ducentis Biotherapeutics
that is new to me? Anyone else?
Good update.
Roll on the 12th July for presentation and Q&A.
2yrs cash runway at least....excellent operational and financial update
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, today announces that its total income and profit after tax for the financial year ended 30 June 2022 is likely to be in-line with market expectations.
During the year the Company made planned investments in the hiring of three new staff members (two technical and the new Head of Business Development) which contributed to net cash outflows of £356k. Despite this, the Company's cash position remains strong, with £687k at the bank as at 30 June 2022, representing almost two years of cash runway. The Directors expect that the hiring of these key staff will translate to increased revenues during the financial year ending 30 June 2023.
The Company is pleased to reflect that over the course of the financial year ended 30 June 2022 it signed new or follow-on business with Merck KGaA, Numab Therapeutics, Bicycle Therapeutics, Ankyra Therapeutics, Ducentis Biotherapeutics and French big pharma company, Servier. In addition, the Company has progressed its observational clinical trial in Portsmouth, designed to generate data to further validate and develop its personalised dosing software.
Dr Jim Millen, CEO, will deliver a short presentation on this update via the Investor Meet Company platform on 13 July 2022 at 12pm GMT. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am the day before the meeting or at any time during the live presentation
Volume surge here at the mo, mind you, not hard considering we've had naff all for days on end, mainly the 100k seller.
Not surprised
£3mln cap
£900k and record revenues and £750k cash ( March results)
Huge client list
No need for funding UNLIKE lots of bio 5echs last 6mths
I've been adding a small amount more today
Lets hope it continues, with some news hopefully. GLA
A late splurge of buys yesterday, we ended positive for the first time in days. long may it continue.
Apologies for the sarcasm but just couldn't help myself!!!
I would say so.
Just about 2 million sold last 2 weeks.
With all these 100k sells, is it same investor?
They gave guidance of about £900k full year revenues and healthy cash position of £750k ish , and working with a growing client base
The year end is today so one would assume they've met or bettered that or would have updated market .
Almost every company is down 50% since January and PYC is no exception ,yet ironically the cash and revenues comapred to market cap is now ludicrous
I would hope that the broker and company would be buying shares soon, there are 850k employee options to be bought as alluded to in the last update .
It's frustrating to be down but Iook at other shares and they are equally baffled